维替泊芬注射粉剂 Verteporfin 商品名 Visudyne，相关性黄斑变性新药，德国产品，一次性进口，平价供应
英文名：Visudyne
商标名：Verteporfin
中文名：维替泊芬
剂型：注射粉剂
生产商：Novartis Pharma GmbH
上市国家：德国
包装规格
维替泊芬注射粉剂：Visudyne Pulver 1x15mg：单价：26500元/人民币
------------------------------------------------------
Visudyne Pulver 15MG（Verteporfin 维替泊芬注射粉剂）
Visudyne Pulver für Infusionslösung
Novartis Pharma GmbH
Produktinformation zu Visudyne Pulver für Infusionslösung ***
Wirksame Bestandteile und Inhaltsstoffe
Verteporfin 15mg
3-sn-Phosphatidylcholin (Eigelb) Hilfstoff
Butylhydroxytoluol Hilfstoff
Colfosceril tetradecanoat Hilfstoff
Lactose 1-Wasser Hilfstoff
Palmitoyl ascorbinsäure Hilfstoff
Erfahrungsberichte zu Visudyne Pulver für Infusionslösung, 15 MG
-----------------------------------------------------
Visudyne(verteporfin for injection)
Visudyne (verteporfin for injection) is a light-activated drug used in photodynamic therapy. Visudyne offers an anatomical treatment that occludes mature vessels that may be expressing less or no VEGF. It works to effect vaso-occlusion of the arteriolarized neovessels that may be the cause of persistent activity.*
Indications and Usage
Visudyne (verteporfin for injection) is indicated for the treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia, or presumed ocular histoplasmosis.
Important Safety Information
Visudyne is contraindicated for patients with porphyria or known hypersensitivity to any component of Visudyne.
Infusion-related transient back pain occurred with Visudyne only. Verteporfin infusion induces temporary photosensitivity; patients should avoid exposure of skin and eyes to direct sunlight or bright indoor light for 5 days. To prevent extravasation, avoid fragile hand veins in favor of larger antecubital veins.
Severe vision decrease (≥4 lines) was reported within 7 days in 1% to 5% of patients. Partial recovery occurs in some patients. Do not re-treat these patients until vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully weighed.
The most frequently reported adverse events (10% to 30% incidence) were injection site reactions (including extravasation and rashes), blurred vision, decreased visual acuity, and visual field defects. |
